Cannabidiol Chewing Gum Cleared for Trial in The Netherlands

Cannabidiol Chewing Gum Cleared for Trial in The Netherlands
Science & Medicine

Axim Biotechnologies has received approval from the Medical Ethical Committee (METC) of Wageningen University in The Netherlands to launch a trial of cannabidiol-containing chewing gum for the treatment of irritable bowel syndrome (IBS). The study will involve Axim’s CanChew Plus chewing gum product. [1]

Axim is the major investment company behind Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the U.S.

Dr. Stuart Titus, CEO of Medical Marijuana, Inc., said:

“We congratulate Axim on yet another step forward toward full clinical trials on cannabis-based treatments. With the global treatment market for irritable bowel syndrome estimated to grow in value to $1.5 billion by 2023, cannabis-based products like CanChew Plus can provide viable solutions for patients suffering from some of the most common of functional gastrointestinal disorders.

It is the goal of our family of companies and for Axim to help people suffering from various gastrointestinal disorders with no effective remedies such as IBD and Crohn’s disease. Positive outcomes from these type of studies can help in the immediate need to enter trials for inflammatory bowel disease (IBD) and Crohn’s disease.” [1]

Axim gained notoriety after releasing its first product, CanChew, in all 50 U.S. states. CanChew uses pharmaceutical-grade, 99.9% pure cannabidiol (CBD) crystals, which are absorbed through the mouth. CanChew Plus – the product approved for the trial in The Netherlands – contains natural botanical hemp oil. It has been used in other clinical trials to treat IBS. [2]

The company’s latest product, MedChew RX, contains both CBD and THC, and is currently being tested in clinical trials. The gum is expected to be used to treat multiple sclerosis-related pain and muscle spasms. Phase III clinical trials of MedChew RX are expected to wrap up by the 3rd or 4th quarter of 2017. After that, Axim will submit the product to the FDA and the European Medicines Agency for review.

Source: Multiple Sclerosis News Today

Axim CEO Dr. George Anastassov said that pot-infused chewing gum “should allow for predictable and controlled release of the active ingredients.” [3]

He added that the gum should have a pleasant taste and consistency, and no undesirable side effects. Anastassov also touted the purity of MedChew RX:

“Not every chewing gum with THC is made the same. There are many other products on the market, but none are pure grade without any other contaminates.” [2]

MedChew RX is of superior purity because the company uses its own extraction method for high-purity THC, Anastassov explained. The process also makes the product about 20% cheaper than the current CanChew, which retails at $56 for a pack of 33 sticks of gum.

Sources:

[1] Pharmaceutical Processing

[2] Fox Business News

[3] MarketWatch

Fox Business News

Multiple Sclerosis News Today